David Sinclair, PhD: In 2014, David Sinclair was named by Time Magazine as one of the 100 most influential people in the world. The article cites Sinclair’s 2013 study in which he and his colleagues identified a cause of aging that is potentially reversible, noting that Sinclair’s work makes possible the idea of “living more years with a body that’s robust enough to make the most of them.” His several seminal research papers in Nature, Cell and Science have been reported in most of the leading news media including The Wall Street Journal, New York Times, TIME, and Newsweek.
- Professor in the Genetic Department at Harvard Medical School, Boston.
- Co-Director of the Paul F. Glenn Laboratories for the Biological Mechanisms of Aging.
- Professor at the School of Medicine at The University of New South Wales (UNSW), Sydney.
- Co-founder and Co-chief Editor of the scientific journal Aging.
- Co-founder Sirtris Pharmaceuticals (Cambridge, MA; NASDAQ:SIRT), Genocea Biosciences (Cambridge, MA; NASDAQ:GNCA), OvaScience (Cambridge, MA; NASDAQ:OVAS), Cohbar, BigDataBio and MetroBiotech.
- Consultant for GlaxoSmithKline, InsideTracker, Metrobiotech, and Ovascience.
Awards, Fellowships and Scholarships
American Association for Aging Research Fellowship, Leukemia Society Fellowship, a Ludwig Scholarship, Ellison Medical Foundation Scholarships, Fisher Lectureship, The Australian Commonwealth Prize, a Helen Hay Whitney Postdoctoral Award, The Nathan Shock Award from NIH, Genzyme Outstanding Achievement in Biomedical Science Award, Telluride Technology Award, Innovator of the Year, MERIT Award from the NIA, Nathan Shock Award, The Merck Prize, a “Bio-Innovator Award”, Excellence in Teaching at Harvard Medical School, Denham Harman Research Award, ASMR Medal, Australian Society for Medical Research.
Sinclair obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney in 1995.